ABUS

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Arbutus Biopharma Corp

NASDAQ | ABUS

4.24

USD

$0.00

(

0.00%

)

At Close (As of Oct 14, 2025)

$820.47M

Market Cap

-

P/E Ratio

-0.29

EPS

$5.09

52 Week High

$2.70

52 Week Low

HEALTHCARE

Sector

ABUS Chart

Recent Chart
Price Action

ABUS Technicals

Tags:

ABUS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $4.8M
Total Revenue $6.2M
Cost Of Revenue $1.4M
Costof Goods And Services Sold $1.4M
Operating Income -$76M
Selling General And Administrative $22M
Research And Development $54M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $6.4M
Interest Income $6.6M
Interest Expense $137K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.4M
Income Before Tax -$70M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$70M
Comprehensive Income Net Of Tax -
Ebit -$70M
Ebitda -$68M
Net Income -$70M

Revenue & Profitability

Earnings Performance

ABUS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $132M
Total Current Assets $127M
Cash And Cash Equivalents At Carrying Value $36M
Cash And Short Term Investments $36M
Inventory -
Current Net Receivables $2.4M
Total Non Current Assets $4.4M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments $86M
Other Current Assets $2.3M
Other Non Current Assets -
Total Liabilities $34M
Total Current Liabilities $16M
Current Accounts Payable $2.3M
Deferred Revenue -
Current Debt -
Short Term Debt $483K
Total Non Current Liabilities $19M
Capital Lease Obligations $1.3M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.3M
Other Current Liabilities $5.2M
Other Non Current Liabilities $15M
Total Shareholder Equity $97M
Treasury Stock -
Retained Earnings -$1.3B
Common Stock $1.4B
Common Stock Shares Outstanding $186M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$65M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.4M
Capital Expenditures $182K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $23M
Cashflow From Financing $52M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$70M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $4.8M
Total Revenue $6.2M
Cost Of Revenue $1.4M
Costof Goods And Services Sold $1.4M
Operating Income -$76M
Selling General And Administrative $22M
Research And Development $54M
Operating Expenses $82M
Investment Income Net -
Net Interest Income $6.4M
Interest Income $6.6M
Interest Expense $137K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.4M
Income Before Tax -$70M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$70M
Comprehensive Income Net Of Tax -
Ebit -$70M
Ebitda -$68M
Net Income -$70M

ABUS News

ABUS Profile

Arbutus Biopharma Corp Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Arbutus Biopharma Corporation is a biopharmaceutical company focused on advancing innovative therapies for chronic hepatitis B virus (HBV) infection. Headquartered in Warminster, Pennsylvania, Arbutus is leveraging its proprietary drug development platform to discover and commercialize novel treatments aimed at addressing the unmet medical needs of HBV patients. With a robust pipeline and a commitment to scientific excellence, the company is well-positioned to make significant contributions to the field of hepatology.

VHAI
+66.66%
$0.00
YYAI
-11.76%
$0.15
BURU
-20.39%
$0.40
UGRO
+54.52%
$0.57
NVDA
-4.40%
$180.03
CGBS
-39.47%
$0.03
PLUG
+6.26%
$4.14
BITF
+28.33%
$5.39
NVTS
+26.07%
$12.57
TMQ
+59.90%
$10.49
RGTI
+2.20%
$56.12
CAN
+18.42%
$1.80
DNN
+3.73%
$3.19
INTC
-4.27%
$35.63
LAES
+24.79%
$7.65
BYND
-23.22%
$0.79
JOBY
+8.05%
$18.12
RR
+4.34%
$6.73
RXRX
+6.50%
$5.89
SSKN
+41.55%
$2.18
ITP
+31.05%
$0.34
F
+1.08%
$11.66
EDHL
+114.42%
$1.07
CRML
+28.73%
$29.97
WULF
+10.42%
$15.46
ACHR
+1.91%
$13.01
BBD
+2.10%
$3.15
SOUN
+8.98%
$20.86
NAK
+4.13%
$2.76
TLRY
-5.32%
$1.60
QBTS
+5.93%
$43.03
DVLT
+24.76%
$2.12
IONZ
+11.73%
$2.57
BTBT
+3.25%
$4.13
GPUS
-6.93%
$0.40
TSLA
-1.52%
$429.24
MARA
+9.88%
$22.24
AMD
+0.77%
$218.09
SOFI
+2.68%
$27.87
AXDX
-61.36%
$0.03
CLF
+0.83%
$13.94
QS
+15.57%
$16.98
ERIC
+20.56%
$9.85
RIG
-2.65%
$3.11
ETHD
+6.45%
$3.54
CIFR
+2.70%
$20.89
NIO
-5.15%
$6.81
QUBT
+1.49%
$21.78
NUAI
+30.63%
$3.07
UAMY
+4.24%
$17.42
ASST
-7.69%
$0.99
NOK
+4.28%
$5.47
CLSK
+9.68%
$21.98
PLTR
+1.42%
$179.74
APLD
+2.33%
$35.04
IREN
+8.16%
$69.37
AREC
+36.74%
$6.81
ABAT
+36.59%
$9.22
RF
+2.44%
$25.16
BTG
+0.56%
$5.34
KDLY
-1.56%
$0.85
AAL
+1.90%
$11.74
USAR
-2.72%
$37.62
UUUU
+16.86%
$23.77
PFE
-0.82%
$24.52
BAC
+2.45%
$50.06
SNAP
-1.61%
$7.92
BMNR
-6.84%
$52.96
RMBL
+60.50%
$3.21
MP
+3.78%
$98.66
ADAP
-2.59%
$0.18
AMZN
-1.69%
$216.34
T
+2.11%
$26.13
ADD
-25.47%
$0.05
JBLU
+7.91%
$4.91
ONDS
-3.70%
$10.41
AAPL
+0.04%
$247.77
SRM
+53.27%
$10.30
ATXS
+37.07%
$11.61
HPE
+0.76%
$24.99
IONQ
-5.50%
$77.56
AQMS
+198.89%
$29.62
BCRX
-8.59%
$6.43
EOSE
-0.41%
$16.98
NAKA
-7.78%
$0.78
KDP
+2.32%
$26.42
GRAB
-0.33%
$5.91
RGTZ
-4.94%
$8.84
GWH
-15.91%
$7.61
BULL
-0.08%
$11.73
DFLI
-2.54%
$1.53
ABEV
+1.16%
$2.16
VALE
+2.41%
$11.01
NB
+3.09%
$11.67
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
GDXD
+3.16%
$0.75
FHN
+2.47%
$23.00
WWR
+29.29%
$2.56
VHAI
+66.66%
$0.00
YYAI
-11.76%
$0.15
BURU
-20.39%
$0.40
UGRO
+54.52%
$0.57
NVDA
-4.40%
$180.03
CGBS
-39.47%
$0.03
PLUG
+6.26%
$4.14
BITF
+28.33%
$5.39
NVTS
+26.07%
$12.57
TMQ
+59.90%
$10.49
RGTI
+2.20%
$56.12
CAN
+18.42%
$1.80
DNN
+3.73%
$3.19
INTC
-4.27%
$35.63
LAES
+24.79%
$7.65
BYND
-23.22%
$0.79
JOBY
+8.05%
$18.12
RR
+4.34%
$6.73
RXRX
+6.50%
$5.89
SSKN
+41.55%
$2.18
ITP
+31.05%
$0.34
F
+1.08%
$11.66
EDHL
+114.42%
$1.07
CRML
+28.73%
$29.97
WULF
+10.42%
$15.46
ACHR
+1.91%
$13.01
BBD
+2.10%
$3.15
SOUN
+8.98%
$20.86
NAK
+4.13%
$2.76
TLRY
-5.32%
$1.60
QBTS
+5.93%
$43.03
DVLT
+24.76%
$2.12
IONZ
+11.73%
$2.57
BTBT
+3.25%
$4.13
GPUS
-6.93%
$0.40
TSLA
-1.52%
$429.24
MARA
+9.88%
$22.24
AMD
+0.77%
$218.09
SOFI
+2.68%
$27.87
AXDX
-61.36%
$0.03
CLF
+0.83%
$13.94
QS
+15.57%
$16.98
ERIC
+20.56%
$9.85
RIG
-2.65%
$3.11
ETHD
+6.45%
$3.54
CIFR
+2.70%
$20.89
NIO
-5.15%
$6.81
QUBT
+1.49%
$21.78
NUAI
+30.63%
$3.07
UAMY
+4.24%
$17.42
ASST
-7.69%
$0.99
NOK
+4.28%
$5.47
CLSK
+9.68%
$21.98
PLTR
+1.42%
$179.74
APLD
+2.33%
$35.04
IREN
+8.16%
$69.37
AREC
+36.74%
$6.81
ABAT
+36.59%
$9.22
RF
+2.44%
$25.16
BTG
+0.56%
$5.34
KDLY
-1.56%
$0.85
AAL
+1.90%
$11.74
USAR
-2.72%
$37.62
UUUU
+16.86%
$23.77
PFE
-0.82%
$24.52
BAC
+2.45%
$50.06
SNAP
-1.61%
$7.92
BMNR
-6.84%
$52.96
RMBL
+60.50%
$3.21
MP
+3.78%
$98.66
ADAP
-2.59%
$0.18
AMZN
-1.69%
$216.34
T
+2.11%
$26.13
ADD
-25.47%
$0.05
JBLU
+7.91%
$4.91
ONDS
-3.70%
$10.41
AAPL
+0.04%
$247.77
SRM
+53.27%
$10.30
ATXS
+37.07%
$11.61
HPE
+0.76%
$24.99
IONQ
-5.50%
$77.56
AQMS
+198.89%
$29.62
BCRX
-8.59%
$6.43
EOSE
-0.41%
$16.98
NAKA
-7.78%
$0.78
KDP
+2.32%
$26.42
GRAB
-0.33%
$5.91
RGTZ
-4.94%
$8.84
GWH
-15.91%
$7.61
BULL
-0.08%
$11.73
DFLI
-2.54%
$1.53
ABEV
+1.16%
$2.16
VALE
+2.41%
$11.01
NB
+3.09%
$11.67
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
WLGS
-5.57%
$0.04
GDXD
+3.16%
$0.75
FHN
+2.47%
$23.00
WWR
+29.29%
$2.56
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.